ArticleCureus2025
Prospective Assessment of Gonadotropin Therapy and Its Outcome in Nonobstructive Azoospermic Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Micro-TESE in Non-Obstructive Azoospermia: Phenotype-Guided Hormonal Optimization and Testosterone Response-Prognostic Biomarker or Therapeutic Target?Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The absence of spermatozoa in the ejaculate after centrifugation is known as azoospermia. The primary purpose of the study was to determine the recombinant gonadotropin therapy on stimulating spermatogenesis in nonobstructive azoospermia (NOA) patients having spermatogenic failure. Additionally, the treatment's clinical outcome and potential adverse effects were evaluated. Materials and methods It was a prospective single-arm observational study and included 20 patients. The study is conducted at the Department of Urology and Infertility Clinics, Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, Bihar, India. It lasted over the period from November 2023 to December 2024. The institutional ethics committee (IEC) of IGIMS granted ethical approval under letter number 1271/IEC/IGIMS/2023, dated 05 October 2023. Results The mean age of the patients in our study was 31.45 ± 4.82 years. The mean initial follicle-stimulating hormone (FSH) level was 16.69±6.02 IU/l, the mean initial luteinizing hormone (LH) was 9.85 ± 1.95 IU/l, and the mean testosterone level at baseline was found to be 9.95 ± 2.54 nmol/l. The association of sperm extraction with late maturation arrest compared to other histopathological findings was found to be statistically significant with a p-value of <0.001. Conclusion It was concluded in the study that gonadotropin therapy is helpful in very selected cases of nonobstructive azoospermia. For men with NOA and spermatogenic failure, recombinant gonadotropin therapy appears to be a useful method of overcoming infertility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.